Pomegranate (Punica granatum L.) is one of the most concentrated dietary sources of polyphenols documented in the literature. What sets it apart from other antioxidants is not only its density of punicalagins and ellagic acid, but the fact that it acts as a bioactive prodrug modulated by the gut microbiota: colon bacteria transform its polyphenols into urolithins, metabolites with activity on mitochondrial function. This page covers composition, mechanism, clinical evidence, bioavailability and metabotypes.
What is pomegranate?
Pomegranate is the fruit of the pomegranate tree (Punica granatum L.), a tree native to the region stretching from Iran to northern India and naturalized for millennia throughout the Mediterranean basin. Botanically, it belongs to the Lythraceae family and produces a globular fruit with a thick, leathery rind that houses hundreds of arils —the seeds surrounded by juicy pulp— of intense red colour.
What makes pomegranate especially interesting from a nutritional standpoint is not its vitamin profile —modest compared with other fruits— but its polyphenol density. Comparative in vitro antioxidant capacity assays consistently place pomegranate juice among the most potent in the catalogue of commercial juices. This antioxidant capacity measured in vitro is a useful indicator but, as we will see later, it does not automatically translate into equivalent effects in the body.
Why pomegranate is different from other dietary antioxidants
The most singular feature of pomegranate is not its antioxidant density but its mechanism: a large part of the fruit's most characteristic polyphenols (the punicalagins) are not absorbed intact in the small intestine. They reach the colon, where the gut microbiota hydrolyses them to release ellagic acid, and this in turn is metabolized by specific bacteria to produce urolithins. Urolithins are the metabolites with the greatest systemic bioavailability and are responsible for much of the biological effects attributable to pomegranate consumption. Pomegranate therefore behaves more like a bioactive prodrug than a direct antioxidant: its effect depends on each person's gut microbial composition.
Main polyphenols: punicalagins, ellagic acid and anthocyanins
Pomegranate concentrates its polyphenols mainly in three parts of the fruit: the rind (peel), the arils (pulp and seed) and the juice. The distribution is not homogeneous: the rind, which is usually discarded, contains polyphenol concentrations far higher than those of the juice. This is why the standardized pomegranate extracts used in supplementation are usually derived from the rind or from the whole fruit, not only from the juice.
Punicalagins
These are the most abundant and characteristic polyphenols of pomegranate. They are high-molecular-weight hydrolysable ellagitannins which, after ingestion, are metabolized by the gut microbiota to release ellagic acid. Punicalagins are responsible for a majority share of the in vitro antioxidant activity of pomegranate juice, making them the main contributors to its characteristic antioxidant potency. They are practically exclusive to pomegranate and the pomegranate tree —they are not found in significant amounts in any other common food source— which makes this fruit the primary dietary source of these compounds.
Ellagic acid and ellagitannins
Ellagic acid is the hydrolysis product of punicalagins and other ellagitannins. It has limited bioavailability in its free form and a short plasma half-life. Its real biological value comes from acting as a precursor of urolithins, the metabolites produced by the colon microbiota from ellagic acid. Walnuts, strawberries and raspberries also contain ellagitannins in smaller amounts, but pomegranate and the pomegranate tree are the dietary source with the highest documented concentration.
Anthocyanins
Responsible for the intense red colour of the arils and the juice, pomegranate anthocyanins mainly include delphinidin-3-glucoside, cyanidin-3-glucoside and pelargonidin-3-glucoside. They are potent free-radical scavengers and have shown anti-inflammatory activity in cell and animal models. Their concentration varies depending on the fruit variety, the growing conditions and the extraction process.
Other phenols
Pomegranate also contains gallic acid, catechins, chlorogenic acid and flavonoids such as quercetin and kaempferol, although in lower concentrations. These compounds contribute to the total antioxidant profile and can act synergistically with punicalagins and anthocyanins.
Summary table of the main pomegranate polyphenols:
| Compound | Main location | Key antioxidant mechanism |
|---|---|---|
| Punicalagins | Rind, juice | Free-radical scavenging, metal chelation, precursors of ellagic acid |
| Ellagic acid | Rind, juice | NF-κB inhibition, precursor of urolithins via the microbiota |
| Urolithins (metabolites) | Produced in the colon by the microbiota | Selective mitophagy, mitochondrial function |
| Anthocyanins | Arils, juice | ROS scavenging, modulation of inflammatory pathways |
| Gallic acid | Rind, juice | Radical scavenging, chelating activity |
Unique mechanism: microbiota → urolithins → mitophagy
This is the section that distinguishes pomegranate from other dietary polyphenols. Urolithins are not found in pomegranate or in any other food source: they are metabolites generated de novo by specific colon bacteria (especially of the genus Gordonibacter) from the ellagic acid released by the punicalagins. Urolithin A is the most studied metabolite for its capacity to induce selective mitophagy —the process by which cells eliminate damaged mitochondria— and to improve mitochondrial function.
Clinical evidence on urolithin A
A Phase 1 clinical trial published in Nature Metabolism documented that oral administration of urolithin A is safe in healthy humans and induces a plasma molecular profile consistent with improved mitochondrial and cellular function. Subsequently, a 4-month randomized clinical trial in middle-aged adults published in Cell Reports Medicine documented improvements in muscle strength, exercise performance and biomarkers of mitochondrial health versus placebo. These results are the scientific basis for the growing interest in urolithin A as an independent bioactive compound, and by extension in pomegranate as the dietary source of the precursor.
Urolithin metabotypes: population variability
The research group of Selma, Tomás-Barberán and García-Villalba has characterized the inter-individual variability in urolithin production and has classified the population into three metabotypes according to the metabolites detectable after consuming foods rich in ellagitannins (pomegranate, walnut):
- Metabotype A (UM-A): mainly produces urolithin A. Approximately 40% of the Western population.
- Metabotype B (UM-B): produces a mix of urolithin A, urolithin B and isourolithin A. Approximately 25-30% of the population.
- Metabotype 0 (UM-0): does not produce detectable urolithins. Between 25% and 40% of the Western population, with variation between cohorts.
This variability has direct implications: two people with the same pomegranate intake can obtain very different systemic effects depending on their gut microbiota. It is one of the factors that explains the heterogeneity of results between clinical trials on pomegranate and the divergence between the in vitro antioxidant activity (high) and the systemic clinical effects (variable). The individual metabotype is not known without a specific test, but it is a factor to bear in mind when interpreting the personal response to pomegranate supplementation.
Antioxidant and anti-inflammatory mechanisms
Beyond the microbiota-urolithins axis, pomegranate polyphenols act on oxidative stress and inflammation through four complementary mechanisms well characterized in vitro and in animal models.
1. Direct free-radical scavenging
Punicalagins, ellagic acid and anthocyanins are direct scavengers of reactive oxygen species (ROS) thanks to their chemical structure: the phenolic hydroxyl groups donate electrons to the radicals, neutralizing them. This is the most immediate mechanism and has been widely documented in in vitro assays using techniques such as DPPH, ABTS and ORAC.
2. Chelation of metal ions
Ions such as iron (Fe²⁺) and copper (Cu²⁺) catalyse the production of hydroxyl radicals through the Fenton reaction. Pomegranate polyphenols have chelating capacity: they bind to these ions and reduce their availability to catalyse oxidative reactions. It is a mechanism especially relevant in contexts of iron overload or in tissues with high metabolic activity.
3. Activation of the Nrf2 pathway
The Nrf2 pathway (Nuclear factor erythroid 2-related factor 2) is the main transcriptional regulator of the endogenous antioxidant response. When activated, Nrf2 translocates to the cell nucleus and binds to the antioxidant response element (ARE) in the DNA, inducing the expression of endogenous antioxidant enzymes such as superoxide dismutase (SOD), catalase, glutathione peroxidase and heme oxygenase-1 (HO-1). Studies in cell and animal models have documented that ellagic acid and punicalagins activate this pathway, amplifying the cellular antioxidant defence beyond the direct effect of the polyphenols themselves.
4. Inhibition of NF-κB
NF-κB (Nuclear factor kappa-light-chain-enhancer of activated B cells) is a central transcriptional regulator of the inflammatory response. Pomegranate polyphenols inhibit several steps of its activation cascade, reducing the transcription of pro-inflammatory genes encoding cytokines such as IL-1β, IL-6 and TNF-α, as well as enzymes such as COX-2 and iNOS. This modulation is the mechanistic basis of most studies on pomegranate and systemic inflammatory markers.
Nuanced clinical evidence
Informational note: The information in this section is for educational purposes and is based on published scientific research. It does not constitute medical advice or a therapeutic recommendation. The conditions mentioned require specialist medical diagnosis and follow-up. Always consult your doctor before starting any supplementation, especially if you take medication.
Blood pressure
This is the area with the most consistent clinical evidence on pomegranate. A systematic review and meta-analysis by Sahebkar et al. published in Pharmacological Research (8 randomized clinical trials) documented that pomegranate juice consumption significantly reduced systolic blood pressure (MD: −4.96 mmHg; 95% CI: −7.67 to −2.25; p<0.001) and diastolic blood pressure (MD: −2.01 mmHg; 95% CI: −3.71 to −0.31; p=0.021). A later systematic review and meta-analysis by Bahari et al. published in Phytotherapy Research with 22 clinical trials (n=2,315 participants) confirmed the direction and magnitude of the effect, with more marked systolic pressure reductions in participants with baseline pressure >130 mmHg. A meta-analysis by Ghaemi et al. in the same journal observed that the antihypertensive effect was dose-dependent and attenuated after 2 months of continued consumption.
Systemic inflammation (CRP, IL-6)
The evidence on systemic inflammatory markers has evolved in recent years. An early meta-analysis by Sahebkar et al. published in Phytomedicine on the effect of pomegranate juice on plasma C-reactive protein found no significant effect. A more recent meta-analysis with more trials published in Phytotherapy Research by Jazinaki et al. (using GRADE methodology to assess the quality of the evidence) and another meta-analysis by Bahari et al. in Inflammopharmacology that included 33 clinical trials did document significant reductions in CRP and IL-6 with pomegranate supplementation, although with relevant methodological heterogeneity between studies. The evidence is therefore nuanced: positive in aggregate but not uniform across meta-analyses.
Overall cardiometabolic health
A dose-response systematic review and meta-analysis published in Nutrition, Metabolism and Cardiovascular Diseases by Mohammadi et al. with 53 randomized clinical trials and 2,306 participants consolidated the evidence on multiple cardiometabolic risk factors: it documented reductions in systolic and diastolic blood pressure, a decrease in total cholesterol, an increase in HDL, a reduction in fasting glucose and modest decreases in body weight and body mass index. No substantial changes were observed in triglycerides, LDL cholesterol, HOMA-IR or glycated haemoglobin.
Urolithin A and muscle function
The line of research on urolithin A as an isolated compound has focused on populations with age-related mitochondrial dysfunction. The Phase 1 trial by Andreux et al. published in Nature Metabolism established the safety profile and the biomarkers of mitochondrial improvement. The randomized trial by Singh et al. published in Cell Reports Medicine in middle-aged adults, with 4 months of supplementation with urolithin A, documented improvements in muscle strength, physical performance and mitochondrial biomarkers versus placebo. These results are the most direct evidence of the pomegranate → ellagic acid → urolithin A → mitochondrial function axis, although urolithin A was administered as a synthetic compound directly, not from pomegranate.
Other areas of research
Clinical trials on pomegranate have been published in metabolic syndrome, joint health, cognitive health and type 2 diabetes. The methodological quality and sample sizes are heterogeneous, and the results are promising but more preliminary than those available for blood pressure. Several meta-analyses point to common limitations: modest sample sizes, short duration (4-12 weeks in most cases) and heterogeneity in the forms of administration (juice, extract, capsules). The effects are consistent in direction but the magnitude is variable.
Bioavailability and A/B/0 metabotypes
Bioavailability is the critical factor that determines whether pomegranate polyphenols produce relevant systemic effects. The antioxidant activity measured in vitro does not automatically translate into equivalent effects in vivo, because the polyphenols must survive the digestive process, be metabolized or absorbed in the intestine and reach the target tissues in sufficient concentrations.
Absorption: what reaches the colon, what reaches the plasma
Punicalagins are not absorbed intact in the small intestine because of their high molecular weight. In the colon, they are hydrolysed by the microbiota to release ellagic acid, which can be partially absorbed, although its bioavailability as such is limited and its plasma half-life is short. The true magnitude of the systemic effect of pomegranate depends on how much ellagic acid is transformed into urolithins, and this transformation is the one that is highly variable between individuals.
Factors that influence bioavailability
| Factor | Impact on bioavailability |
|---|---|
| Individual gut microbiota | Determines urolithin production and the magnitude of the systemic effect (main factor) |
| Form of consumption | Freshly pressed juice retains punicalagins better than long-life pasteurized juice |
| Industrial processing | Commercial juice may have lost part of its punicalagins during storage |
| Dose | The dose-response relationship is not fully established; very high doses do not guarantee a proportionally greater effect in metabotype 0 |
| Food matrix | The presence of fibre and other polyphenols can modulate colonic fermentation |
| Age and state of the microbiota | Gut dysbiosis can alter urolithin production |
Forms of consumption and studied doses
Clinical trials on pomegranate have used three main forms of administration: juice, standardized extract and whole fruit (arils).
| Form | Dose used in clinical studies | Considerations |
|---|---|---|
| Pomegranate juice | 150-240 mL/day | Choose 100% pure, with no added sugars. Prefer cold-pressed and without aggressive pasteurization |
| Standardized extract | 200-1,000 mg/day (as punicalagins or total polyphenols) | Greater dose reproducibility; useful when a specific and constant concentration is sought |
| Whole fruit (arils) | Variable according to consumption | Provides fibre and vitamin C; lower relative concentration of punicalagins than rind extract |
The minimum duration of the interventions in clinical studies that have documented significant effects on blood pressure and inflammation ranges from 4 to 12 weeks. Consistency over time appears to be more relevant than the one-off dose.
Important note: the doses mentioned correspond to those used in research. They do not constitute a recommendation of an individual dose. Consult your doctor or pharmacist before starting any supplementation, especially if you take medication.
Safety and drug interactions
Consuming pomegranate as fruit or juice in usual amounts is considered safe for most healthy adults. The available clinical trials, with durations of up to 12 weeks, have not reported serious adverse effects. The most relevant safety consideration is drug interactions, which should be kept in mind especially with concentrated extracts.
Inhibition of CYP3A4 and P-glycoprotein
Pomegranate polyphenols can inhibit cytochrome P450 3A4 (CYP3A4) and P-glycoprotein, two key systems in the metabolism of numerous drugs. This inhibition can increase the plasma concentrations of medications metabolized by these pathways, including:
- Statins (atorvastatin, simvastatin): risk of myopathy and elevation of transaminases at high doses.
- Oral anticoagulants (warfarin): risk of increased anticoagulant effect and bleeding.
- Immunosuppressants (ciclosporin, tacrolimus): risk of toxicity due to increased plasma levels.
- Some antihypertensives and antiarrhythmics.
If you take any of these medications, consult your doctor or pharmacist before incorporating pomegranate extract supplements. Occasional consumption of fruit or juice in moderate amounts is less likely to cause a clinically relevant interaction than daily supplementation with standardized extract.
Allergy (uncommon)
Isolated cases of allergic reaction to pomegranate have been described, including urticaria, angioedema and, in very rare cases, anaphylaxis. People with a known allergy to other fruits (especially peach, cherry or apple) should introduce pomegranate with caution.
Sugar content of the juice
Pomegranate juice contains natural sugars (around 12-14 g per 100 mL). People with type 2 diabetes, insulin resistance or who follow low-carbohydrate diets should take this contribution into account and consult their health professional.
Pregnancy, breastfeeding and concentrated extracts
Consuming the whole fruit or juice in moderate amounts during pregnancy and breastfeeding is generally considered safe. The evidence on concentrated extracts in these populations is limited and caution is recommended until specific studies exist.
How to choose a pomegranate supplement
The market offers a wide variety of pomegranate products, from juice to standardized extracts of very different quality. The key technical criteria:
- Standardization in punicalagins or total polyphenols: serious products state the percentage of punicalagins or total polyphenols (typically 30-40% total polyphenols or a specific percentage of punicalagins A+B). Without standardization, the actual concentration is unpredictable.
- Origin of the raw material: extracts derived from the rind or from the whole fruit concentrate more punicalagins than those derived only from the juice.
- Traceability and purity analysis: presence of analysis for heavy metals (rinds can accumulate cadmium and others), pesticides and adulterants.
- No added sugars in the case of juice: if the option is juice, it must be 100% juice without sugary additives.
- Consistency with the studied dose: extract ranges between 200-1,000 mg/day are those used in clinical research.
Pomegranate in the Pleniage portfolio
In the formulation of PLENIAGE® ANTIOX PRO, pomegranate (100 mg as standardized extract) is incorporated together with other components of the cellular antioxidant system: NAC 300 mg, glutathione 120 mg, CoQ10 100 mg, turmeric 100 mg, astaxanthin 4 mg, lutein 4 mg and lycopene 6 mg. Each ingredient has its own individual scientific research; the specific combination of this formula has not been the subject of its own clinical trial. Pomegranate contributes its distinctive feature as a dietary precursor of urolithins via the microbiota, complementing the direct antioxidant mechanisms of the other ingredients.
This page is part of the Antioxidants and defences cluster. To explore other related components in more depth, see the Turmeric page (complementary anti-inflammatory modulator in the formula) and the Glutathione page (endogenous antioxidant related to the Nrf2 pathway).
Frequently asked questions about pomegranate
What makes pomegranate special compared with other antioxidant fruits?
Pomegranate stands out for two combined reasons. First, its polyphenol density: it contains punicalagins, ellagitannins practically exclusive to this fruit, in concentrations far higher than other fruits. Second, its unique mechanism: punicalagins are not absorbed intact; instead they reach the colon and are transformed by the gut microbiota into urolithins, metabolites with significant systemic bioavailability and activity on mitochondrial function. Pomegranate is therefore a bioactive prodrug modulated by the microbiota, not just a direct antioxidant.
Why does the response to pomegranate vary so much between people?
Because of differences in individual gut microbiota. The production of urolithins from ellagic acid depends on specific colon bacteria (especially of the genus Gordonibacter). The research group of Selma, Tomás-Barberán and García-Villalba has classified the population into three metabotypes: Met A (~40% produce urolithin A), Met B (~25-30% produce a mix of urolithins) and Met 0 (~25-40% do not produce detectable urolithins). Two people with the same pomegranate intake can obtain very different systemic effects depending on their metabotype.
Is fresh pomegranate juice or extract in capsules better?
It depends on the goal. Fresh juice provides polyphenols together with vitamins, fibre (if the arils are consumed) and other compounds of the natural matrix, but its punicalagin concentration can vary depending on the variety and processing. Standardized extracts offer a more predictable and reproducible concentration, which makes them preferable when a specific and constant dose is sought. Both forms have shown efficacy in clinical trials on blood pressure and inflammation.
Does pomegranate lower blood pressure?
This is the area with the most consistent clinical evidence. Several systematic reviews and meta-analyses (Sahebkar et al. 2017 in Pharmacological Research, Bahari et al. 2024 in Phytotherapy Research, Ghaemi et al. 2023 in the same journal) have documented significant reductions in systolic and diastolic blood pressure with the consumption of pomegranate juice or extract. The magnitude is modest but consistent and greater in people with elevated baseline pressure. Pomegranate does not replace prescribed antihypertensive drug treatment; people with diagnosed hypertension should consult their doctor.
Does pomegranate interact with medications?
Yes, especially concentrated extracts. Pomegranate polyphenols inhibit cytochrome P450 3A4 (CYP3A4) and P-glycoprotein, systems involved in the metabolism of numerous drugs. The most relevant interactions are with statins (risk of myopathy), oral anticoagulants such as warfarin (risk of bleeding), immunosuppressants such as ciclosporin and tacrolimus (risk of toxicity) and some antihypertensives. If you take any of these medications, consult your doctor or pharmacist before starting supplementation with pomegranate extract.
Does pomegranate have effects on cellular ageing?
The most promising research focuses on urolithin A, the metabolite derived from pomegranate ellagic acid. A Phase 1 trial published in Nature Metabolism (Andreux et al. 2019) and a 4-month randomized trial published in Cell Reports Medicine (Singh et al. 2022) in middle-aged adults documented improvements in mitochondrial biomarkers and muscle function following supplementation with urolithin A. It is important to note that these studies used synthetic urolithin A administered directly, not pomegranate. People with metabotype 0 do not produce urolithins from pomegranate consumption and therefore might not obtain this specific benefit through diet.
Pomegranate is not a miracle remedy or a substitute for healthy lifestyle habits. Its value lies in being an exceptionally concentrated source of polyphenols with a unique mechanism in the human diet —the microbiota-urolithins axis— and with clinical evidence that is consistent for blood pressure and promising for other cardiometabolic markers. Inter-individual variability by metabotype is a critical factor to consider when interpreting the personal response. If you are interested in exploring antioxidant and anti-inflammatory strategies in more depth, consult your doctor or pharmacist to assess whether pomegranate supplementation is appropriate for your situation.
At PLENIAGE® we publish scientific content on evidence-based supplementation. You can explore the Antioxidants and defences cluster for more pages and related articles.
References
The statements in the article are based on available scientific literature. Below are the key verified references that support the main claims about pomegranate and the associated polyphenols (urolithins).
- Sahebkar A, Ferri C, Giorgini P, Bo S, Nachtigal P, Grassi D. Effects of pomegranate juice on blood pressure: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2017;115:149-161. PMID: 27888156.
- Bahari H, Omidian K, Goudarzi K, et al. The effects of pomegranate consumption on blood pressure in adults: A systematic review and meta-analysis. Phytother Res. 2024;38(5):2234-2248. PMID: 38410857.
- Ghaemi F, Emadzadeh M, Atkin SL, Jamialahmadi T, Zengin G, Sahebkar A. Impact of pomegranate juice on blood pressure: A systematic review and meta-analysis. Phytother Res. 2023. PMID: 37461211.
- Mohammadi S, Heshmati J, Baziar N, Ziaei S, et al. Impacts of supplementation with pomegranate on cardiometabolic risk factors: A systematic review and dose-response meta-analysis. Nutr Metab Cardiovasc Dis. 2025. PMID: 40617711.
- Sahebkar A, Gurban C, Serban A, Andrica F, Serban MC. Effects of supplementation with pomegranate juice on plasma C-reactive protein concentrations: A systematic review and meta-analysis of randomized controlled trials. Phytomedicine. 2016;23(11):1095-1102. PMID: 26922037.
- Jazinaki MS, et al. The effect of pomegranate juice supplementation on C-reactive protein levels: GRADE-assessed systematic review and dose-response updated meta-analysis. Phytother Res. 2024. PMID: 38553998.
- Andreux PA, Blanco-Bose W, Ryu D, et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nat Metab. 2019;1(6):595-603. PMID: 32694802.
- Singh A, D'Amico D, Andreux PA, et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell Rep Med. 2022;3(5):100633. PMID: 35584623.
- Selma MV, González-Sarrías A, Salas-Salvadó J, et al. The gut microbiota metabolism of pomegranate or walnut ellagitannins yields two urolithin-metabotypes that correlate with cardiometabolic risk biomarkers. Clin Nutr. 2018;37(3):897-905. PMID: 28347564.